S 95035
Alternative Names: S-095035; S-95035Latest Information Update: 17 May 2024
At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action MAT2A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 29 Apr 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in Australia (PO) (NCT06188702)
- 03 Jan 2024 Servier plans phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in March 2024 (PO) (NCT06188702)
- 28 Nov 2023 Phase-I clinical trials in Solid tumours (PO) (Servier pipeline; November 2023)